

SEQUENCE LISTING

<110> Evotec NeuroSciences GmbH

<120> Diagnostic and Therapeutic Use of the human DAX-1 gene
and protein for neurodegenerative diseases

<130> 042327wo Me/FM

<140> PCT/EP2004/052684

<141> 2004-10-28

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 470

<212> PRT

<213> Homo sapiens

<400> 1

Met Ala Gly Glu Asn His Gln Trp Gln Gly Ser Ile Leu Tyr Asn Met
1 5 10 15

Leu Met Ser Ala Lys Gln Thr Arg Ala Ala Pro Glu Ala Pro Glu Thr
20 25 30

Arg Leu Val Asp Gln Cys Trp Gly Cys Ser Cys Gly Asp Glu Pro Gly
35 40 45

Val Gly Arg Glu Gly Leu Leu Gly Gly Arg Asn Val Ala Leu Leu Tyr
50 55 60

Arg Cys Cys Phe Cys Gly Lys Asp His Pro Arg Gln Gly Ser Ile Leu
65 70 75 80

Tyr Ser Met Leu Thr Ser Ala Lys Gln Thr Tyr Ala Ala Pro Lys Ala
85 90 95

Pro Glu Ala Thr Leu Gly Pro Cys Trp Gly Cys Ser Cys Gly Ser Asp
100 105 110

Pro Gly Val Gly Arg Ala Gly Leu Pro Gly Gly Arg Pro Val Ala Leu
115 120 125

Leu Tyr Arg Cys Cys Phe Cys Gly Glu Asp His Pro Arg Gln Gly Ser
130 135 140

Ile Leu Tyr Ser Leu Leu Thr Ser Ser Lys Gln Thr His Val Ala Pro
145 150 155 160

Ala Ala Pro Glu Ala Arg Pro Gly Gly Ala Trp Trp Asp Arg Ser Tyr
165 170 175

Phe Ala Gln Arg Pro Gly Gly Lys Glu Ala Leu Pro Gly Gly Arg Ala
180 185 190

Thr	Ala	Leu	Leu	Tyr	Arg	Cys	Cys	Phe	Cys	Gly	Glu	Asp	His	Pro	Gln		
		195					200					205					
Gln	Gly	Ser	Thr	Leu	Tyr	Cys	Val	Pro	Thr	Ser	Thr	Asn	Gln	Ala	Gln		
	210					215					220						
Ala	Ala	Pro	Glu	Glu	Arg	Pro	Arg	Ala	Pro	Trp	Trp	Asp	Thr	Ser	Ser		
225					230					235					240		
Gly	Ala	Leu	Arg	Pro	Val	Ala	Leu	Lys	Ser	Pro	Gln	Val	Val	Cys	Glu		
				245					250					255			
Ala	Ala	Ser	Ala	Gly	Leu	Leu	Lys	Thr	Leu	Arg	Phe	Val	Lys	Tyr	Leu		
			260					265					270				
Pro	Cys	Phe	Gln	Val	Leu	Pro	Leu	Asp	Gln	Gln	Leu	Val	Leu	Val	Arg		
	275						280					285					
Asn	Cys	Trp	Ala	Ser	Leu	Leu	Met	Leu	Glu	Leu	Ala	Gln	Asp	Arg	Leu		
	290					295					300						
Gln	Phe	Glu	Thr	Val	Glu	Val	Ser	Glu	Pro	Ser	Met	Leu	Gln	Lys	Ile		
305					310				315					320			
Leu	Thr	Thr	Arg	Arg	Arg	Glu	Thr	Gly	Gly	Asn	Glu	Pro	Leu	Pro	Val		
			325					330					335				
Pro	Thr	Leu	Gln	His	His	Leu	Ala	Pro	Pro	Ala	Glu	Ala	Arg	Lys	Val		
		340					345					350					
Pro	Ser	Ala	Ser	Gln	Val	Gln	Ala	Ile	Lys	Cys	Phe	Leu	Ser	Lys	Cys		
	355					360						365					
Trp	Ser	Leu	Asn	Ile	Ser	Thr	Lys	Glu	Tyr	Ala	Tyr	Leu	Lys	Gly	Thr		
	370					375					380						
Val	Leu	Phe	Asn	Pro	Asp	Val	Pro	Gly	Leu	Gln	Cys	Val	Lys	Tyr	Ile		
385					390				395					400			
Gln	Gly	Leu	Gln	Trp	Gly	Thr	Gln	Gln	Ile	Leu	Ser	Glu	His	Thr	Arg		
			405					410					415				
Met	Thr	His	Gln	Gly	Pro	His	Asp	Arg	Phe	Ile	Glu	Leu	Asn	Ser	Thr		
		420					425					430					
Leu	Phe	Leu	Leu	Arg	Phe	Ile	Asn	Ala	Asn	Val	Ile	Ala	Glu	Leu	Phe		
	435					440					445						
Phe	Arg	Pro	Ile	Ile	Gly	Thr	Val	Ser	Met	Asp	Asp	Met	Met	Leu	Glu		
	450				455					460							
Met	Leu	Cys	Thr	Lys	Ile												
465				470													

<211> 2022
 <212> DNA
 <213> Homo sapiens

<400> 2
 gagctccac gctgctgttc ttccatttcc agctttttaa gagcaccgc cccttcgaac 60
 caccgaggtc atgggcgaac acaccggagc gcagaccgcg ccccccgca cacaccgccc 120
 gcctccgcgc ccttgcccag accgaggcgg ccgacgcgcg tgcgtgcgcg ctaggtataa 180
 ataggtccca ggaggcagcc actgggcaga actgggctac gggcgccgcg ggccatggcg 240
 ggcgagaacc accagtggca gggcagcatc ctctacaaca tgcttatgag cgcgaagcaa 300
 acgcgcgcgc ctctgaggc tccagagacg cggctggtgg atcagtgttg gggctgttcg 360
 tgcggcgatg agcccgggt gggcagagag gggctgctgg gcgggcggaa cgtggcgctc 420
 ctgtaccgct gctgcttttg cggtaaagac caccacggc agggcagcat cctctacagc 480
 atgctgacga gcgcaaagca aacgtacgcg gcaccgaagg cggccgaggc gacgctgggt 540
 ccgtgctggg gctgttcgtg cggctctgat cccggggtgg gcagagcggg gcttccgggt 600
 gggcgcccg tggcactcct gtaccgctgc tgcctttgtg gtgaagacca cccgcggcag 660
 ggcagcatcc tctacagctt gctcactagc tcaaagcaaa cgcacgtggc tccggcagcg 720
 cccgaggcac ggccaggggg cgcgtggtgg gaccgctcct acttcgcgcg gaggccaggg 780
 ggtaaagagg cgctaccagg cgggcggggc acggcgcttc tgtaccgctg ctgcttttgc 840
 ggtgaagacc accgcagca gggcagcacc ctctactgcg tgcccacgag cacaaatcaa 900
 gcgcaggcgc ctccggagga gcggccgagg gcccctggt gggacacctc ctctggtgcg 960
 ctgcggccgc tggcgctcaa gagtccacag gtggtctgcg aggcagcctc agcgggcctg 1020
 ttgaagacgc tgcgcttcgt caagtacttg ccctgcttcc aggtgctgcc cctggaccag 1080
 cagctggtgc tgggtgcgca ctgctgggcg tccctgctca tgcttgagct ggcccaggac 1140
 cgcttgagc tgcgactgt ggaagtctcg gagccagca tgctgcagaa gatcctcacc 1200
 accaggcggc gggagaccgg gggcaacgag cactgcccg tgcccacgct gcagcaccat 1260
 ttggcaccgc cggcgaggc caggaagggt ccctccgct cccaggcca agccatcaag 1320
 tgctttcttt ccaaagtctg gagtctgaac atcagtacca aggagtacg ctacctcaag 1380
 gggaccgtgc tctttaaccc ggacgtgccc ggctgagc gcgtgaagta cattcaggga 1440
 ctccagtggg gaactcagca aatactcagt gaacacacca ggatgacgca ccaagggccc 1500
 catgacagat tcatcgaact taatagtacc cttttcctgc tgagattcat caatgccaat 1560
 gtcattgctg aactgttctt caggcccatc atcggcacag tcagcatgga tgatatgatg 1620
 ctggaatgca tctgtacaaa gatataaagt catgtgggac acacaagtgc agtagtgag 1680
 ttaccatga gggagaata aagagctgtg ggcaaaagag tgtaaaatat tttaaaataa 1740
 actttcttaa tatttttaca tgcagagtat tttgatcttc aattaaagaa ataattttat 1800
 tcccagcaca gtcacaaatt tctctgttcc atagttaaag aagacatttg ccaacaggta 1860
 gcatagctct gtacatcttt taaaaaaaa atcgcagggt actagtataa taagctattt 1920
 tcacaagcgc agcaatttca tggaaacctg tcaaatcaaa tttgtacata ttgttataat 1980
 aaattttaag gtcttaacta ttaacttgat tgaaaaaagc tt 2022

<210> 3
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer for the
 DAX-1 gene

<400> 3
 taccaaggag tacgcctacc tca

<210> 4
 <211> 20
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for the
DAX-1 gene

<400> 4

cacgtccggg ttaaagagca

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for the
cyclophilin B gene

<400> 5

actgaagcac tacgggcctg

20

<210> 6

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for the
cyclophilin B gene

<400> 6

agccgttggt gtctttgcc

19

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for the
ribosomal protein S9 gene

<400> 7

ggtcaaattt accctggcca

20

<210> 8

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer for the
ribosomal protein S9 gene

<400> 8
tctcatcaag cgtcagcagt tc 22

<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
beta-actin gene

<400> 9
tggaacggtg aaggtgaca 19

<210> 10
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
beta-actin gene

<400> 10
ggcaaggac ttctgtaa 19

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
GAPDH gene

<400> 11
cgtcatgggt gtgaacctg 20

<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
GAPDH gene

<400> 12
gctaagcagt tgggtggtgca g 21

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
transferrin receptor gene

<400> 13
gtcgtgtggtc agttcgtgat t 21

<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
transferrin receptor gene

<400> 14
agcagttggc tgttgtacct ctc 23

<210> 15
<211> 1413
<212> DNA
<213> Homo sapiens

<400> 15
atggcgggcg agaaccacca gtggcagggc agcatcctct acaacatgct tatgagcgcg 60
aagcaaacgc gcgcggctcc tgaggctcca gagacgcggc tgggtggatca gtgttggggc 120
tgttcgtgcg gcgatgagcc cgggggtggc agagaggggc tgctgggcgg gcggaacgtg 180
gcgctcctgt accgctgctg cttttgcggc aaagaccacc cacggcaggg cagcatcctc 240
tacagcatgc tgacgagcgc aaagcaaacg tacgcggcac cgaaggcgcc cgaggcgacg 300
ctgggtccgt gctggggctg ttcgtgcggc tctgatcccg ggggtggcag agcggggctt 360
ccgggtgggc ggcccggtggc actcctgtac cgctgctgct tttgtggtga agaccacccg 420
cggcagggca gcatcctcta cagcttgctc actagctcaa agcaaacgca cgtggctccg 480
gcagcgcccg aggcacggcc agggggcgcg tgggtgggacc gtcctactt cgcgcagagg 540
ccagggggta aagaggcgct accaggcggg cggggccacgg cgcttctgta ccgctgctgc 600
ttttgcggtg aagaccaccc gcagcagggc agcacccctct actgcgtgcc cacgagcaca 660
aatcaagcgc aggcggctcc ggaggagcgg ccgagggccc cctgggtggga cacctcctct 720
ggtgcgctgc ggccgggtggc gctcaagagt ccacaggtgg tctgcgaggc agcctcagcg 780
ggcctgttga agacgctgcy cttcgtcaag tacttgccct gcttccaggt gctgcccctg 840
gaccagcagc tgggtgctggt gcgcaactgc tgggcgtccc tgcctcatgct tgagctggcc 900
caggaccgct tgcagttcga gactgtggaa gtctcggagc ccagcatgct gcagaagatc 960
ctcaccacca ggcggcggga gaccgggggc aacgagccac tgcccgtgcc cacgctgcag 1020
caccatttgg caccgcgggc ggaggccagg aagggtgccct ccgcctccca ggtccaagcc 1080
atcaagtgtc ttctttccaa atgctggagt ctgaacatca gtaccaagga gtacgcctac 1140
ctcaagggga ccgtgctctt taacccggac gtgcccgggc tgcagtgcgt gaagtacatt 1200
cagggaactc agtggggaac tcagcaaata ctcagtgaac acaccaggat gacgcaccaa 1260
gggccccatg acagattcat cgaacttaat agtacccttt tcctgctgag attcatcaat 1320
gccaatgtca ttgctgaact gttcttcagg cccatcatcg gcacagtcag catggatgat 1380
atgatgctgg aaatgctctg tacaaagata taa 1413

Docket No.: 37998-237364
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Von Der Kammer et al.

Art Unit: Not Yet Assigned

Application No: 10/595,619

Examiner: Not Yet Assigned

Confirmation No: 3638

Filed: May 1, 2006

Atty. Docket No: 37998-237364

For: DIAGNOSTIC AND THERAPEUTIC USE
OF THE HUMAN DAX-1 GENE AND
PROTEIN FOR NEURODEGENERATIVE
DISEASES

Customer No:

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In order to comply with the duty of disclosure pursuant to 37 C.F.R. § 1.56, submitted herewith is a form listing the documents cited in the International Search Report of International

Application No. PCT/EP2004/053573. The relevance of each document is indicated in the International Search Report.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237364. A duplicate copy of this paper is enclosed.

Dated: May 7, 2007

Respectfully submitted,

By Kavita B. Lepping
Kavita B. Lepping
Registration No.: 54,262
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

DC2/856087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/595,619-Conf. #3638
				Filing Date	May 1, 2006
				First Named Inventor	Heinz Von Der Kammer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	37998-237364

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-2002/068815	06-06-2002	Edward R. McCabe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Zanaria, Elena et al., "An unusual member of the nuclear hormone receptor superfamily responsible for x-linked adrenal hypoplasia congenita," Nature, vol. 372, no. 6507, 1994, pgs. 635-641	
	CB	Guo, Weiwen et al., "Expression of DAX-1, the gene responsible of X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis," Biochemical and Molecular Medicine, vol. 56, no. 1, 1995, pgs. 8-13	
	CC	Kopp, Peter, "Targeted disruption of the Ahch (Dax-1) gene: Knockout of old concepts," European Journal of Endocrinology, vol. 140, no. 4, April 1999, pgs. 291-292	
	CD	Eckey, Maren et al., "Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors," Molecular and Cellular Endocrinology, vol. 213, no. 1, 12/31/2003, pgs. 71-78	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/052684

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 G01N33/50 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/068815 A1 (MCCABE EDWARD R. B ET AL) 6 June 2002 (2002-06-06) abstract paragraphs '0013!, '0017!, '0018!, '0136! - '0149!; claims 8,14,20; example 3	3,9
A	ZANARIA ELENA ET AL: "An unusual member of the nuclear hormone receptor superfamily responsible for x-linked adrenal hypoplasia congenita" NATURE (LONDON), vol. 372, no. 6507, 1994, pages 635-641, XP002339051 ISSN: 0028-0836 abstract page 638, column 2, paragraphs 2,3 ----- -/--	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

4 August 2005

Date of mailing of the international search report

22/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klee, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/052684

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, A	ECKEY MAREN ET AL: "Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors." MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 213, no. 1, 31 December 2003 (2003-12-31), pages 71-78, XP002339011 ✓ ISSN: 0303-7207 abstract page 75, column 2, paragraph 2 - page 77, column 1, paragraph 5 -----	1-16
A	GUO WEIWEN ET AL: "Expression of DAX-1, the gene responsible of X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis" BIOCHEMICAL AND MOLECULAR MEDICINE, vol. 56, no. 1, 1995, pages 8-13, ✓ XP002339052 ISSN: 1077-3150 cited in the application abstract page 10, column 1, paragraph 4 - page 12, column 1, paragraph 1 -----	1-16
X	KOPP PETER: "Targeted disruption of the Ahch (Dax-1) gene: Knockout of old concepts" EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 140, no. 4, April 1999 (1999-04), pages 291-292, XP002339200 ✓ ISSN: 0804-4643 the whole document -----	4,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/052684

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002068815 A1	06-06-2002	AU 6601096 A WO 9704810 A1	26-02-1997 13-02-1997
